CL2015002608A1 - Compuesto de amino-pirazol y usos medicinales relacionados. - Google Patents

Compuesto de amino-pirazol y usos medicinales relacionados.

Info

Publication number
CL2015002608A1
CL2015002608A1 CL2015002608A CL2015002608A CL2015002608A1 CL 2015002608 A1 CL2015002608 A1 CL 2015002608A1 CL 2015002608 A CL2015002608 A CL 2015002608A CL 2015002608 A CL2015002608 A CL 2015002608A CL 2015002608 A1 CL2015002608 A1 CL 2015002608A1
Authority
CL
Chile
Prior art keywords
amino
pyrazole compound
medicinal uses
related medicinal
pyrazole
Prior art date
Application number
CL2015002608A
Other languages
English (en)
Inventor
Takahisa Motomura
Gakujun Shomi
Original Assignee
Japan Tobacco Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51536938&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2015002608(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Japan Tobacco Inc filed Critical Japan Tobacco Inc
Publication of CL2015002608A1 publication Critical patent/CL2015002608A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C39/00—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring
    • C07C39/23—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring polycyclic, containing six-membered aromatic rings and other rings, with unsaturation outside the aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/76—Esters of carboxylic acids having a carboxyl group bound to a carbon atom of a six-membered aromatic ring
    • C07C69/78—Benzoic acid esters

Abstract

Compuestos derivados de pirazol-amida y sus sales farmacéuticamente aceptables, como inhibidores de piruvato deshidrogenasa cinasa; composición farmacéutica que los comprende, útil para la profilaxis o tratamiento de diabetes, hiperglicemia, insuficiencia cardiaca, EPOC, entre otras enfermedades.
CL2015002608A 2013-03-15 2015-09-11 Compuesto de amino-pirazol y usos medicinales relacionados. CL2015002608A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361791164P 2013-03-15 2013-03-15
JP2013053195 2013-03-15
JP2013127318 2013-06-18

Publications (1)

Publication Number Publication Date
CL2015002608A1 true CL2015002608A1 (es) 2016-03-04

Family

ID=51536938

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2015002608A CL2015002608A1 (es) 2013-03-15 2015-09-11 Compuesto de amino-pirazol y usos medicinales relacionados.

Country Status (31)

Country Link
US (4) US9040717B2 (es)
EP (3) EP2975028B1 (es)
JP (6) JP6208603B2 (es)
KR (1) KR102226096B1 (es)
CN (1) CN105051015B (es)
AU (1) AU2014230569B2 (es)
BR (1) BR112015022077A2 (es)
CA (1) CA2904985C (es)
CL (1) CL2015002608A1 (es)
CY (1) CY1120173T1 (es)
DK (1) DK2975028T3 (es)
ES (1) ES2663789T3 (es)
HK (1) HK1215808A1 (es)
HR (1) HRP20180635T1 (es)
HU (1) HUE036672T2 (es)
IL (1) IL241355B (es)
LT (1) LT2975028T (es)
ME (1) ME03090B (es)
MX (1) MX2015012743A (es)
MY (1) MY182884A (es)
NO (1) NO2975028T3 (es)
PE (1) PE20151595A1 (es)
PH (1) PH12015501993B1 (es)
PL (1) PL2975028T3 (es)
PT (1) PT2975028T (es)
RS (1) RS57188B1 (es)
RU (1) RU2664532C2 (es)
SG (1) SG11201507327TA (es)
SI (1) SI2975028T1 (es)
TW (1) TWI633885B (es)
WO (1) WO2014142290A1 (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6437452B2 (ja) 2013-01-14 2018-12-12 インサイト・ホールディングス・コーポレイションＩｎｃｙｔｅ Ｈｏｌｄｉｎｇｓ Ｃｏｒｐｏｒａｔｉｏｎ Ｐｉｍキナーゼ阻害剤として有用な二環式芳香族カルボキサミド化合物
ME03780B (me) 2013-01-15 2021-04-20 Incyte Holdings Corp Jedinjenja tiazolkarboksamida i piridinkarboksamida korisna kao inhibitori pim kinaze
DK2975028T3 (en) * 2013-03-15 2018-03-12 Japan Tobacco Inc PYRAZOLAMIDE COMPOUND AND MEDICAL APPLICATIONS THEREOF
WO2015027124A1 (en) 2013-08-23 2015-02-26 Incyte Corporation Furo- and thieno-pyridine carboxamide compounds useful as pim kinase inhibitors
US9580418B2 (en) 2014-07-14 2017-02-28 Incyte Corporation Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors
US9822124B2 (en) 2014-07-14 2017-11-21 Incyte Corporation Bicyclic heteroaromatic carboxamide compounds useful as Pim kinase inhibitors
US9540347B2 (en) 2015-05-29 2017-01-10 Incyte Corporation Pyridineamine compounds useful as Pim kinase inhibitors
AR105967A1 (es) 2015-09-09 2017-11-29 Incyte Corp Sales de un inhibidor de pim quinasa
TW201718546A (zh) 2015-10-02 2017-06-01 英塞特公司 適用作pim激酶抑制劑之雜環化合物
EP3492452B1 (en) * 2016-07-29 2022-08-31 Japan Tobacco Inc. Production method for pyrazole-amide compound
US10596161B2 (en) 2017-12-08 2020-03-24 Incyte Corporation Low dose combination therapy for treatment of myeloproliferative neoplasms
WO2019151274A1 (ja) * 2018-02-01 2019-08-08 日本たばこ産業株式会社 含窒素複素環アミド化合物及びその医薬用途
JPWO2020054734A1 (ja) 2018-09-11 2021-08-30 日本たばこ産業株式会社 ピラゾール−アミド化合物を含有する慢性腎臓病の治療又は予防剤
KR20210135266A (ko) 2019-03-04 2021-11-12 니뽄 다바코 산교 가부시키가이샤 피라졸-아미드 화합물의 비정질 고체 분산체
JP2022007994A (ja) * 2020-03-04 2022-01-13 日本たばこ産業株式会社 縮合三環性化合物及びその医薬用途
AU2022337617A1 (en) * 2021-09-01 2024-04-18 Japan Tobacco Inc. Nitrogen-containing tricyclic compound and pharmaceutical use thereof
KR20240045387A (ko) * 2022-09-28 2024-04-08 (주)제이디바이오사이언스 신규한 플루오렌 유도체 및 이의 용도

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2827285B1 (fr) * 2001-07-10 2003-12-05 Rhodia Chimie Sa Reactif et procede pour la perfluoroalcoylation
TWI329111B (en) 2002-05-24 2010-08-21 X Ceptor Therapeutics Inc Azepinoindole and pyridoindole derivatives as pharmaceutical agents
US7098241B2 (en) 2002-12-16 2006-08-29 Hoffmann-La Roche Inc. Thiophene hydroxamic acid derivatives
CA2521784C (en) 2003-04-08 2012-03-27 Yeda Research And Development Co. Ltd. Reversible pegylated drugs
KR20070000389A (ko) 2004-02-20 2007-01-02 아스텔라스세이야쿠 가부시키가이샤 플루오렌 유도체
FR2885904B1 (fr) 2005-05-19 2007-07-06 Aventis Pharma Sa Nouveaux derives du fluorene, compositions les contenant et utilisation
RU2007147844A (ru) * 2005-05-23 2009-06-27 Джапан Тобакко Инк. (Jp) Пиразольное соединение и содержащее его терапевтическое средство для лечения сахарного диабета
US7767685B2 (en) * 2006-06-29 2010-08-03 King Pharmaceuticals Research And Development, Inc. Adenosine A2B receptor antagonists
FR2936173B1 (fr) * 2008-09-22 2012-09-21 Snecma Procede pour la fabrication d'une piece en titane avec forgeage initial dans le domaine beta
AR074797A1 (es) 2008-10-10 2011-02-16 Japan Tobacco Inc Compuesto de fluoreno , composiciones farmaceuticas , inhibidores de pdhk y pdhk2 , metodos de tratamiento , usos de los mismos y kit comercial
JPWO2010123016A1 (ja) * 2009-04-22 2012-10-25 アステラス製薬株式会社 カルボン酸化合物
DK2975028T3 (en) * 2013-03-15 2018-03-12 Japan Tobacco Inc PYRAZOLAMIDE COMPOUND AND MEDICAL APPLICATIONS THEREOF
US20140296316A1 (en) 2013-03-15 2014-10-02 Japan Tobacco Inc. Hydrate and crystal of fluorene compounds
JP2015028010A (ja) 2013-07-01 2015-02-12 日本たばこ産業株式会社 フルオレン−アミド化合物およびその医薬用途
TW201536749A (zh) 2013-07-01 2015-10-01 Japan Tobacco Inc 吡唑－醇化合物及其醫藥用途

Also Published As

Publication number Publication date
ME03090B (me) 2019-01-20
KR20150131221A (ko) 2015-11-24
CY1120173T1 (el) 2018-12-12
JP2019194197A (ja) 2019-11-07
US20180256547A1 (en) 2018-09-13
PH12015501993A1 (en) 2016-01-11
IL241355B (en) 2019-03-31
EP3805205A1 (en) 2021-04-14
ES2663789T3 (es) 2018-04-17
US20160074364A1 (en) 2016-03-17
PL2975028T3 (pl) 2018-10-31
HK1215808A1 (zh) 2016-09-15
TWI633885B (zh) 2018-09-01
CA2904985C (en) 2021-07-20
EP2975028B1 (en) 2018-02-21
SI2975028T1 (en) 2018-07-31
SG11201507327TA (en) 2015-10-29
HUE036672T2 (hu) 2018-07-30
JP2015024984A (ja) 2015-02-05
BR112015022077A2 (pt) 2017-07-18
CA2904985A1 (en) 2014-09-18
AU2014230569B2 (en) 2017-11-23
PH12015501993B1 (en) 2016-01-11
CN105051015A (zh) 2015-11-11
PT2975028T (pt) 2018-03-29
MX2015012743A (es) 2016-02-19
NO2975028T3 (es) 2018-07-21
EP2975028A4 (en) 2016-08-17
LT2975028T (lt) 2018-04-10
HRP20180635T1 (hr) 2018-06-01
JP2022000453A (ja) 2022-01-04
WO2014142290A1 (ja) 2014-09-18
US9040717B2 (en) 2015-05-26
JP2018188449A (ja) 2018-11-29
KR102226096B1 (ko) 2021-03-09
MY182884A (en) 2021-02-05
IL241355A0 (en) 2015-11-30
EP3348545A1 (en) 2018-07-18
US20140296315A1 (en) 2014-10-02
US20200163937A1 (en) 2020-05-28
AU2014230569A1 (en) 2015-10-08
DK2975028T3 (en) 2018-03-12
CN105051015B (zh) 2018-09-25
TW201501711A (zh) 2015-01-16
EP2975028A1 (en) 2016-01-20
PE20151595A1 (es) 2015-11-24
RU2015144182A3 (es) 2018-03-06
JP2020189855A (ja) 2020-11-26
JP2018021061A (ja) 2018-02-08
RU2015144182A (ru) 2017-04-24
RS57188B1 (sr) 2018-07-31
JP6208603B2 (ja) 2017-10-04
RU2664532C2 (ru) 2018-08-20

Similar Documents

Publication Publication Date Title
CL2015002608A1 (es) Compuesto de amino-pirazol y usos medicinales relacionados.
NI201600058A (es) Compuestos derivados de piridilo bicíclicos fusionados a anillo como inhibidores de fgfr4
SV2015005066A (es) Compuestos de biaril-amida como inhibidores de cinasa
SV2016005137A (es) Derivados de piperidinil-indol como inhibidores del factor de complemento b y usos de los mismos
NI201600018A (es) Derivados de pirrolamida sustituidos con glioxamida y su uso como medicamentos para el tratamiento de la hepatitis b.
SV2015005115A (es) Derivados de la pirazolopirrolidina y su uso en el tratamiento de enfermedades
CL2015003442A1 (es) Derivados heterociclicos
DOP2013000192A (es) Compuestos y composiciones como inhibidores de la trk
BR112016015838A8 (pt) compostos heterocíclicos aromáticos, composição farmacêutica compreendendo os referidos compostos e produto de combinação
CL2014001793A1 (es) Compuestos derivados de 1,3,5-triazinas sustituidas y sus sales, como inhibidores de la idh2 mutante; composicion farmaceutica que los comprende; y su uso para el tratamiento del cancer.
ECSP17013903A (es) Protein kinase c inhibitors and methods of their use
SV2018005687A (es) Derivados de dihidroimidazopirazinona usados en el tratamiento del cancer
AR104984A1 (es) Compuestos selectivos para pyy y sus usos
SV2017005405A (es) Compuestos y composiciones como inhibidores de quinasa raf
UY35485A (es) Compuestos heterocíclicos y usos de los mismos
CL2013001338A1 (es) Compuestos derivados de benzotieno-piridinas sustituidas, inhibidores de la replicacion del vih; composicion farmaceutica que los comprende; combinacion farmaceutica; kit farmaceutico; y su uso para el tratamiento del vih.
CU20160192A7 (es) Derivados de indano e indolina útiles como activadores de la guanilato ciclasa soluble
CL2015000744A1 (es) Combinación de regorafenib y ácido acetilsalicílico para el tratamiento del cáncer.
CL2015001279A1 (es) Compuestos derivados de piridina, inhibidores del transportador de uratos urat 1; composicion farmaceutica que los comprende; uso para el tratamiento o prevencion de enfermedades tales como gota, hiperuricemia, hipertensión, enfermedades renales, entre otras.
DOP2015000170A (es) Compuestos químicos
CL2015000615A1 (es) Compuestos derivados de 4-amino-quinolinas, inhibidores de rip2 cinasa; composicion farmaceutica que los comprende; uso para el tratamiento de enfermedades tales como enfermedad de crohn, colitis ulcerativa o sindrome de blau.
BR112017016817A2 (pt) derivados heterocíclicos formilados como inibidores de fgfr4
UY36875A (es) Composiciones inhibidoras de bromodominios para el tratamiento de diversas enfermedades
SV2016005313A (es) Derivados de carboxamida
PE20150167A1 (es) (r)-nifuratel, su uso para el tratamiento de las infecciones y sintesis de (r) y (s)-nifuratel